Oleg Borisenko, MD, PhD’s Post

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 790+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/eDfUCMnt

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 870+ market access and HEOR projects in Europe for more than 210 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/eDfUCMnt

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 810+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/ersEsFnq

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 810+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/ersEsFnq

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 810+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/ersEsFnq

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 790+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/eDfUCMnt

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 870+ market access and HEOR projects in Europe for more than 210 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/eDfUCMnt

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 790+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/ersEsFnq

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 810+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/ersEsFnq

Analysis of five HTAs of medical technologies in 2023 and strategic recommendations for evidence generation strategy in England. MTRC is the leading provider of reimbursement analysis in Europe. Since 2017 we have accomplished 810+ market access and HEOR projects in Europe for more than 200 companies. We specialize in multi-country assessments and have experience with analysis in 34 EU countries. Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others). MTRC developed an analytical White Paper with review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. Request an analytical White Paper here: https://lnkd.in/ersEsFnq